LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

Search

Amicus Therapeutics Inc

Abierto

Sector Salud

8.81 -1.01

Resumen

Variación precio

24h

Actual

Mínimo

8.73

Máximo

8.92

Métricas clave

By Trading Economics

Ingresos

21M

15M

Ventas

8.2M

150M

BPA

0.09

Margen de beneficio

9.845

Empleados

499

EBITDA

286K

22M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+84.48 upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-138M

2.7B

Apertura anterior

9.82

Cierre anterior

8.81

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

182 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Amicus Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 mar 2025, 23:42 UTC

Acciones populares

Stocks to Watch: Intel, Adobe, Tilly's, SentinelOne

12 mar 2025, 22:48 UTC

Ganancias

Algoma Steel Warns of Effects of Tariffs on Operations

12 mar 2025, 20:45 UTC

Ganancias

Adobe Posts Higher Profit, Revenue in 1Q

12 mar 2025, 23:52 UTC

Principales Noticias
Ganancias

Adobe Stock Slides Despite Earnings Beat. The CFO Is Confident About AI. -- Barrons.com

12 mar 2025, 23:51 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 mar 2025, 23:51 UTC

Charlas de Mercado

Nikkei May Rise as Concerns About U.S. Inflation Ebb -- Market Talk

12 mar 2025, 23:49 UTC

Charlas de Mercado

Gold Edges Higher as Global Trade War Prospects Grow -- Market Talk

12 mar 2025, 23:12 UTC

Ganancias

Longfor Group 2023 Net Profit Was CNY12.85B >0960.HK

12 mar 2025, 23:12 UTC

Ganancias

Longfor Group: Decline in Revenue From Property Development Hurt Results >0960.HK

12 mar 2025, 23:11 UTC

Ganancias

Longfor Group Expects 2024 Net Profit to Decline by Around 20% on Year >0960.HK

12 mar 2025, 22:54 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

12 mar 2025, 22:53 UTC

Charlas de Mercado

Algoma Steel Says Tariffs Will Hurt Finances, Operations -- Market Talk

12 mar 2025, 22:52 UTC

Charlas de Mercado

Intel's New CEO Tan Faces Decisions Regarding Company Structure, AI Strategy -- Market Talk

12 mar 2025, 22:03 UTC

Charlas de Mercado

Alkane's Boda Project Gains Luster as Gold Prices Rise -- Market Talk

12 mar 2025, 21:57 UTC

Charlas de Mercado

Bank of Canada Officials Did Discuss Leaving Policy Rate Unchanged -- Market Talk

12 mar 2025, 21:31 UTC

Charlas de Mercado

Intel's Interim Co-CEOs Will Return to Prior Roles -- Market Talk

12 mar 2025, 21:27 UTC

Principales Noticias

Intel Names Lip-Bu Tan as Chief Executive Officer -- 3rd Update

12 mar 2025, 21:26 UTC

Charlas de Mercado

Intel CEO Sees 'Significant Opportunities' to Remake Business -- Market Talk

12 mar 2025, 21:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 mar 2025, 21:17 UTC

Charlas de Mercado

Intel Names Former Board Member Tan as Permanent CEO -- Market Talk

12 mar 2025, 21:15 UTC

Principales Noticias

Senate GOP's Tax-Cut Wishlist Heads North of $5 Trillion -- WSJ

12 mar 2025, 20:50 UTC

Principales Noticias

Walmart Gets an Earful From China Over Response to Trump Tariffs -- 2nd Update

12 mar 2025, 20:50 UTC

Principales Noticias

Intel Names Lip-Bu Tan as Chief Executive Officer -- 2nd Update

12 mar 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

12 mar 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

12 mar 2025, 20:45 UTC

Principales Noticias

Intel Names Lip-Bu Tan as Chief Executive Officer -- Update

12 mar 2025, 20:43 UTC

Principales Noticias

The Latest Overhaul of Starbucks -- by the Numbers -- Update

12 mar 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Murphy Oil: Reaffirming 2025 Cap Expenditure Guidance Range of $1.135B to $1.285B, With 1Q CAPEX Reaffirmed at $425M >MUR

12 mar 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Murphy Oil: Subsidiary Signed a Purchase and Sale Agreement to Acquire the BW Pioneer Floating Production Storage and Offloading Vessel From BW Offshore >MUR

12 mar 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Murphy Oil: Gross Purchase Price Is $125M, Includes Initial Approximate $100M Payment Upon Delivery by the End 1Q >MUR

Comparación entre iguales

Cambio de precio

Amicus Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

84.48% repunte

Estimación a 12 meses

Media 16.4 USD  84.48%

Máximo 21 USD

Mínimo 12 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

8

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.57 / 9.03Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

182 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.